Q-omics provides the consensus-scored NDUFA7 profile across patient tissues and cancer cell-line models. NDUFA7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFA7 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NDUFA7 RNA expression shows 18,443 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where NDUFA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA7 survival associations across molecular data types. NDUFA7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA7 RNA expression–survival associations across cancer types. High NDUFA7 expression shows unfavorable associations in UVM, ACC, KICH, UCS and LIHC, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFA7 RNA expression.
This table summarizes NDUFA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA7 shows higher tumor expression in KIRC, LIHC, KIRP, BRCA, COAD and CHOL. The KIRC box plot shows higher NDUFA7 RNA expression in tumor versus normal tissue (log2 FC = +0.581, t-test p < 0.001).
This table shows molecular features associated with NDUFA7 in patient tissues and cancer cell lines. In patient samples, NDUFA7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
